The Value Of PD-L1 Immunohistochemical Expression In Egyptian Urinary Bladder Carcinoma Patients

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Urinary bladder carcinoma is a significant health concern.
• Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein implicated in tumor immune evasion.
• Understanding PD-L1 expression is crucial for developing targeted therapies.

Purpose of the Study:

• To evaluate programmed death-ligand 1 (PD-L1) immunohistochemical expression in various urinary bladder carcinoma variants.
• To correlate PD-L1 expression with clinicopathological features of bladder cancer.

Main Methods:

• A retrospective study of 70 formalin-fixed, paraffin-embedded urinary bladder carcinoma specimens.
• Immunohistochemical staining using anti-PD-L1 antibody.
• Analysis of PD-L1 expression in relation to age, gender, and tumor type (noninvasive vs. infiltrating).

Main Results:

• Positive PD-L1 expression was detected in 60% (42/70) of the cases.
• No significant association was found between PD-L1 expression and age, gender, or histopathological type.
• The majority of specimens were from non-Hispanic white males with infiltrating bladder carcinoma.

Conclusions:

• Programmed death-ligand 1 (PD-L1) expression is prevalent in urinary bladder carcinoma.
• PD-L1 may serve as a predictive marker for aggressive bladder cancer.
• Immunohistochemical assessment of PD-L1 could guide patient selection for targeted immunotherapy.